Trials / Active Not Recruiting
Active Not RecruitingNCT06553638
Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.
Conditions
Timeline
- Start date
- 2024-08-12
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
- First posted
- 2024-08-14
- Last updated
- 2024-08-14
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06553638. Inclusion in this directory is not an endorsement.